Site notes
This page validates as XHTML 1.0, and will look much better in a browser that supports web standards. So maybe you should...
This page validates as XHTML 1.0, and will look much better in a browser that supports web standards. So maybe you should...
Sender's message:
Sent on Wednesday, 2007 Sep 12.
Search brain cancer
Click on the following url to view complete results in pubmed. (Results may change over time.)
http://www.ncbi.nlm.nih.gov/entrez/cubby.fcgi?call=0oa8H4SbXOJMF9uyFhJegPLXcDjwacUfKPAn-fOtwF6YdjSXSQe-YUQMaOiccbV&WebCubbyUser=0am-sLicAHJEumk2y351-WZr%401FC027126E893F20_0049SID
To unsubscribe from these e-mail updates click on the following url
http://www.ncbi.nlm.nih.gov/entrez/cubby.fcgi?call=0_HlH9oKRz8_CdEKQAnA38Rls_mKbQbz3N1ujsL8EsbRkQlmW&WebCubbyUser=0am-sLicAHJEumk2y351-WZr%401FC027126E893F20_0049SID
==================== Entrez pubmed Results ======================
Items 1 - 5 of 19
1: J Clin Oncol. 2007 Sep 1;25(25):4023; author reply 4024-5.
Comment on:
J Clin Oncol. 2007 Apr 1;25(10):1260-6.
Avoiding bias in the prospective evaluation of patients with brain metastases.
Vordermark D.
Publication Types:
Comment
Letter
PMID: 17761992 [PubMed - indexed for MEDLINE]
2: J Clin Oncol. 2007 Sep 1;25(25):3915-22.
Prevalence, clinical pattern, and outcome of CNS involvement in childhood and
adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a
Berlin-Frankfurt-Munster Group Report.
Salzburg J, Burkhardt B, Zimmermann M, Wachowski O, Woessmann W, Oschlies I,
Klapper W, Wacker HH, Ludwig WD, Niggli F, Mann G, Gadner H, Riehm H, Schrappe
M, Reiter A.
Department of Pediatric Hematology and Oncology, Justus-Liebig-University,
Giessen, Germany.
PURPOSE: We analyzed the prevalence, clinical pattern, and prognostic impact of
CNS involvement in a large cohort of children and adolescents diagnosed with
non-Hodgkin's lymphoma (NHL), with special attention to differences according to
NHL subtype. PATIENTS AND METHODS: From October 1986 to December 2002, 2,381
patients (median age, 9.37 years; range, 0.2 to 23.8 years; female-to-male
ratio, 1:2.7) from Germany, Austria, and Switzerland were registered. A total of
2,086 patients were eligible for the consecutive multicenter protocols
NHL-Berlin-Frankfurt-Munster [BFM] -86, NHL-BFM-90, and NHL-BFM-95, and could be
evaluated for outcome. RESULTS: CNS involvement was diagnosed in 141 (5.9%) of
2,381 patients and was associated with an advanced stage of NHL. The percentage
of CNS-positive patients was 8.8% for Burkitt's lymphoma/Burkitt's leukemia
(BL/B-ALL), 5.4% for precursor B-lymphoblastic lymphoma (pB-LBL), 3.3% for
anaplastic large-cell lymphoma, 3.2% for T-cell-LBL, 2.6% for diffuse large
B-cell lymphoma, and 0% for primary mediastinal large B-cell NHL (P < .001).
Most CNS-positive patients with pB-LBL, T-LBL, or BL/B-ALL had meningeal
disease. The probability of event-free survival (pEFS; +/- SE) at 5 years was
85% +/- 1% for the 2,086 protocol patients (median follow-up, 6.5 years; range,
0.3 to 17.7 years). For the 112 CNS-positive patients, pEFS was 64% +/- 5%,
compared with 86% +/- 1% for the 1,927 CNS-negative patients (P < .001).
Although CNS disease had no impact on pEFS for advanced-stage T-LBL patients,
CNS-positive patients with BL/B-ALL had a worse average outcome than
CNS-negative patients with stage IV BL/B-ALL (60% +/- 5% v 81% +/- 3%; P <
.001). In multivariate analysis, CNS disease was the strongest predictor for
relapse in BL/B-ALL patients with advanced-stage disease. CONCLUSION: Six
percent of childhood/adolescent NHL patients were CNS positive. However, the
prevalence, pattern, and prognostic impact of CNS involvement differed among NHL
subtypes.
Publication Types:
Research Support, Non-U.S. Gov't
PMID: 17761975 [PubMed - indexed for MEDLINE]
3: Ear Nose Throat J. 2007 Jul;86(7):388-90.
Bilateral cerebellopontine angle metastatic melanoma: a case report.
Jacob A, Brightman RP, Welling DB.
Department of Otolaryngology-Head and Neck Surgery, The Ohio State University
Medical Center, Columbus, OH 43210, USA. abraham.jacob@osumc.edu
Although melanoma accounts for approximately 1% of all malignancies, melanoma
metastases to the cerebellopontine angles (CPAs) are exceedingly rare. Here we
describe a patient with melanoma metastases to the internal auditory canals and
CPAs who presented with a remote history of cutaneous melanoma. This patient had
a rapidly progressive hearing loss, vestibulopathy, and facial nerve
dysfunction. Magnetic resonance imaging demonstrated bilateral, enhancing CPA
lesions but was otherwise nonspecific. The diagnosis required a careful history,
unilateral surgical resection for tissue acquisition, and histopathologic
confirmation. A search for primary cutaneous melanoma at the time of
presentation was negative. However, the history of cutaneous melanoma 8 years
earlier distinguishes this patient's metastatic disease from solitary primary
intracranial melanoma, an equally rare disease. Treatment consists of surgical
excision, radiation, chemotherapy, and immunotherapy. The prognosis for patients
with melanoma metastases is generally poor, but isolated reports of long-term
survival have been described. Metastatic disease to the CPAs must be included in
the differential diagnosis for any patient presenting with rapid-onset VIIth or
VIIIth cranial nerve symptoms.
Publication Types:
Case Reports
PMID: 17702316 [PubMed - indexed for MEDLINE]
4: J Clin Oncol. 2007 Sep 1;25(25):3853-8. Epub 2007 Aug 6.
Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer.
Bartsch R, Wenzel C, Altorjai G, Pluschnig U, Rudas M, Mader RM, Gnant M,
Zielinski CC, Steger GG.
First Department of Medicine and Cancer Centre, Clinical Division of Oncology,
Medical University of Vienna, Vienna, Austria.
PURPOSE: In human epidermal growth factor 2 (HER-2)-positive advanced breast
cancer, taxanes or vinorelbine plus trastuzumab are among the most widely
applied options in the first-line setting. We evaluated the efficacy and
tolerability of capecitabine plus trastuzumab after anthracycline and docetaxel
or vinorelbine failure and prior trastuzumab exposure. PATIENTS AND METHODS:
Forty consecutive patients were included. Capecitabine was administered at a
dose of 1,250 mg/m(2) bid for 14 consecutive days in 3-week cycles, with dose
modifications if necessary. Trastuzumab was administered every 3 weeks. Time to
progression (TTP) was defined as primary end point. Response was evaluated every
3 months using International Union Against Cancer criteria. RESULTS: TTP was a
median of 8 months, and overall survival was 24 months. No significant
difference was found for second-line and beyond second-line treatment. A
complete response (CR) was observed in 2.5%, partial response (PR) in 17.5%,
stable disease lasting at least 6 months (SD) in 50%, resulting in a clinical
benefit rate (CR + PR + SD > or = 6 months) of 70%. Diarrhea (5%) and hand-foot
syndrome (15%) were the only treatment-related adverse events that occurred with
grade 3 or 4 intensity. Three patients (7.5%) developed brain metastases while
receiving therapy. CONCLUSION: Capecitabine plus trastuzumab appears to be an
effective and safe option in a heavily pretreated population. Therefore, a
direct comparison of this regimen with capecitabine monotherapy in this setting
is warranted.
Publication Types:
Clinical Trial
PMID: 17679724 [PubMed - indexed for MEDLINE]
5: Cancer Res. 2007 Aug 1;67(15):7505-11.
A growth hormone receptor mutation impairs growth hormone autofeedback signaling
in pituitary tumors.
Asa SL, Digiovanni R, Jiang J, Ward ML, Loesch K, Yamada S, Sano T, Yoshimoto K,
Frank SJ, Ezzat S.
Department of Pathology, University Health Network and Toronto Medical
Laboratories, Mount Sinai Hospital, Ontario Cancer Institute, Toronto, Ontario,
Canada. sylvia.asa@uhn.on.ca
Pituitary tumors are a diverse group of neoplasms that are classified based on
clinical manifestations, hormone excess, and histomorphologic features. Those
that cause growth hormone (GH) excess and acromegaly are subdivided into
morphologic variants that have not yet been shown to have pathogenetic
significance or predictive value for therapy and outcome. Here, we identify a
selective somatic histidine-to-leucine substitution in codon 49 of the
extracellular domain of the GH receptor (GHR) in a morphologic subtype of human
GH-producing pituitary tumors that is characterized by the presence of
cytoskeletal aggresomes. This GHR mutation significantly impairs
glycosylation-mediated receptor processing, maturation, ligand binding, and
signaling. Pharmacologic GH antagonism recapitulates the morphologic phenotype
of pituitary tumors from which this mutation was identified, inducing the
formation of cytoskeletal keratin aggresomes. This novel GHR mutation provides
evidence for impaired hormone autofeedback in the pathogenesis of these
pituitary tumors. It explains the lack of responsiveness to somatostatin
analogue therapy of this tumor type, in contrast to the exquisite sensitivity of
tumors that lack aggresomes, and has therapeutic implications for the safety of
GH antagonism as a therapeutic modality in acromegaly.
Publication Types:
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
PMID: 17671221 [PubMed - indexed for MEDLINE]